Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × brolucizumab × CNS × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neurofibromatosis 2 1 Macular Degeneration 1

Interventions

Temozolomide 77 Radiotherapy 37 Bevacizumab 32 Radiosurgery 20 Magnetic Resonance Spectroscopy 16 Cyclophosphamide 16 Radiation 13 Irinotecan 13 Carboplatin 12 Topotecan 11 Filgrastim 10 Radiotherapy, Intensity-Modulated 9 Nivolumab 9 Etoposide 9 Erlotinib Hydrochloride 9 pembrolizumab 8 Lomustine 8 Granulocyte Colony-Stimulating Factor 8 Granulocyte-Macrophage Colony-Stimulating Factor 7 Everolimus 7 Carmustine 7 sargramostim 6 antineoplaston AS 2-1 6 antineoplaston A10 6 TPI-287 6 Mental Status and Dementia Tests 6 Melphalan 6 Isotretinoin 6 Ipilimumab 6 Imatinib Mesylate 6

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03710564 2023-01-30

MERLIN

Novartis

Phase 3 Terminated

535 enrolled 14 charts

Macular Degeneration, Neurofibromatosis 2

Data powered by HemOnc (CC BY 4.0) Colophon ⚡